ATE202704T1 - Verwendung eines natrium- oder lysiniumsalzes von crotonsäureamidderivaten zur herstellung eines arzneimittels zur behandlung von krebserkrankungen - Google Patents
Verwendung eines natrium- oder lysiniumsalzes von crotonsäureamidderivaten zur herstellung eines arzneimittels zur behandlung von krebserkrankungenInfo
- Publication number
- ATE202704T1 ATE202704T1 AT96116408T AT96116408T ATE202704T1 AT E202704 T1 ATE202704 T1 AT E202704T1 AT 96116408 T AT96116408 T AT 96116408T AT 96116408 T AT96116408 T AT 96116408T AT E202704 T1 ATE202704 T1 AT E202704T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- crotonic acid
- sodium
- producing
- acid amide
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- NQQRXZOPZBKCNF-NSCUHMNNSA-N (e)-but-2-enamide Chemical class C\C=C\C(N)=O NQQRXZOPZBKCNF-NSCUHMNNSA-N 0.000 title 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- KDXKERNSBIXSRK-UHFFFAOYSA-O lysinium(1+) Chemical class [NH3+]CCCCC([NH3+])C([O-])=O KDXKERNSBIXSRK-UHFFFAOYSA-O 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 229910052708 sodium Inorganic materials 0.000 title 1
- 239000011734 sodium Substances 0.000 title 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical class C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19539638A DE19539638A1 (de) | 1995-10-25 | 1995-10-25 | Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE202704T1 true ATE202704T1 (de) | 2001-07-15 |
Family
ID=7775689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96116408T ATE202704T1 (de) | 1995-10-25 | 1996-10-14 | Verwendung eines natrium- oder lysiniumsalzes von crotonsäureamidderivaten zur herstellung eines arzneimittels zur behandlung von krebserkrankungen |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US5886033A (enExample) |
| EP (1) | EP0769296B1 (enExample) |
| JP (1) | JP3996658B2 (enExample) |
| AT (1) | ATE202704T1 (enExample) |
| CA (1) | CA2188228C (enExample) |
| DE (2) | DE19539638A1 (enExample) |
| DK (1) | DK0769296T3 (enExample) |
| ES (1) | ES2160197T3 (enExample) |
| GR (1) | GR3036754T3 (enExample) |
| PT (1) | PT769296E (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1012150A4 (en) * | 1997-05-19 | 2002-05-29 | Sugen Inc | HETEROARYLCARBOXAMIDE COMPOUNDS THAT ARE EFFECTIVE OF DISEASES CAUSED BY PROTEIN-TYROSIN-KINASE |
| US6316479B1 (en) | 1997-05-19 | 2001-11-13 | Sugen, Inc. | Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders |
| DK0987256T3 (da) * | 1997-08-08 | 2002-02-11 | Aventis Pharma Gmbh | Krystalform af N-(4-trifluormethylphenyl)-5-methylisoxazol-4-carboxylsyreamid |
| EP0933633A1 (en) | 1997-12-11 | 1999-08-04 | Hoechst Marion Roussel Deutschland GmbH | Process for obtaining L-dihydroorotic acid and use thereof |
| DE19857009A1 (de) * | 1998-12-10 | 2000-06-15 | Aventis Pharma Gmbh | Zubereitung mit verbesserter therapeutischer Breite, enthaltend Nukleotidsyntheseinhibitoren |
| WO2004056746A1 (en) | 2002-12-23 | 2004-07-08 | 4Sc Ag | Cycloalkene dicarboxylic acid compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| US7247736B2 (en) * | 2002-12-23 | 2007-07-24 | 4Sc Ag | Method of identifying inhibitors of DHODH |
| US7365094B2 (en) | 2002-12-23 | 2008-04-29 | 4Sc Ag | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| CN101006065B (zh) | 2004-06-17 | 2012-07-11 | 英菲尼蒂发现公司 | 抑制bcl蛋白与结合伴侣的相互作用的化合物和方法 |
| US7842815B2 (en) | 2004-06-17 | 2010-11-30 | Infinity Pharmaceuticals, Inc. | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners |
| DE102006014165A1 (de) * | 2006-03-24 | 2007-09-27 | Schebo Biotech Ag | Neue Isooxazol-Derivate und deren Verwendungen |
| TWI389895B (zh) | 2006-08-21 | 2013-03-21 | Infinity Discovery Inc | 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法 |
| CN108472280A (zh) * | 2015-09-01 | 2018-08-31 | 布罗德研究所股份有限公司 | 用于治疗或者预防血液癌症的化合物和方法 |
| CN111423374B (zh) * | 2020-05-18 | 2023-03-21 | 合肥工业大学 | 一种二氢吡唑磺酰胺类化合物及其制备方法和用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL186239B (nl) * | 1975-06-05 | Hoechst Ag | Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze. | |
| DE2854439A1 (de) * | 1978-12-16 | 1980-07-03 | Hoechst Ag | Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung |
| DE59010701D1 (de) * | 1990-05-18 | 1997-05-22 | Hoechst Ag | Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung |
| IL99811A (en) * | 1990-10-30 | 1996-03-31 | Roussel Uclaf | 3-cycloalkyl-propanamides their tautomer forms and their salts preparation process and compositions containing them |
| ES2079765T3 (es) * | 1991-10-23 | 1996-01-16 | Hoechst Ag | Derivados de amidas de acido n-fenil-2-ciano-3-hidroxicrotonico y su utilizacion como medicamento con propiedad inmunomoduladora. |
| GB9200275D0 (en) * | 1992-01-08 | 1992-02-26 | Roussel Lab Ltd | Chemical compounds |
| GB9320299D0 (en) * | 1993-10-01 | 1993-11-17 | Roussel Lab Ltd | Isoxazole derivatives |
| US5700823A (en) * | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
| US5519042A (en) * | 1994-01-13 | 1996-05-21 | Hoechst Aktiengesellschaft | Method of treating hyperproliferative vascular disease |
-
1995
- 1995-10-25 DE DE19539638A patent/DE19539638A1/de not_active Withdrawn
-
1996
- 1996-10-14 DK DK96116408T patent/DK0769296T3/da active
- 1996-10-14 ES ES96116408T patent/ES2160197T3/es not_active Expired - Lifetime
- 1996-10-14 EP EP96116408A patent/EP0769296B1/de not_active Expired - Lifetime
- 1996-10-14 PT PT96116408T patent/PT769296E/pt unknown
- 1996-10-14 DE DE59607208T patent/DE59607208D1/de not_active Expired - Lifetime
- 1996-10-14 AT AT96116408T patent/ATE202704T1/de active
- 1996-10-16 US US08/733,050 patent/US5886033A/en not_active Expired - Lifetime
- 1996-10-18 CA CA002188228A patent/CA2188228C/en not_active Expired - Fee Related
- 1996-10-24 JP JP28191896A patent/JP3996658B2/ja not_active Expired - Fee Related
-
1998
- 1998-11-13 US US09/191,375 patent/US6020372A/en not_active Expired - Lifetime
-
2001
- 2001-09-28 GR GR20010401611T patent/GR3036754T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2188228C (en) | 2008-08-12 |
| DK0769296T3 (da) | 2001-10-22 |
| EP0769296A1 (de) | 1997-04-23 |
| DE59607208D1 (de) | 2001-08-09 |
| PT769296E (pt) | 2001-11-30 |
| CA2188228A1 (en) | 1997-04-26 |
| JPH09165336A (ja) | 1997-06-24 |
| JP3996658B2 (ja) | 2007-10-24 |
| ES2160197T3 (es) | 2001-11-01 |
| US6020372A (en) | 2000-02-01 |
| EP0769296B1 (de) | 2001-07-04 |
| GR3036754T3 (en) | 2001-12-31 |
| DE19539638A1 (de) | 1997-04-30 |
| US5886033A (en) | 1999-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE202704T1 (de) | Verwendung eines natrium- oder lysiniumsalzes von crotonsäureamidderivaten zur herstellung eines arzneimittels zur behandlung von krebserkrankungen | |
| DE69100079D1 (de) | Naphthalin-derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen. | |
| DE19680619D2 (de) | Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs | |
| ATE132145T1 (de) | Verfahren zur herstellung von bacchatin iii und von desacetyl-10-bacchatin iii derivate | |
| FI954243A0 (fi) | Farmaseuttiset yhdisteet | |
| PT88526A (pt) | L-dopa derivatives or their acid addition salts process for producing same and their use | |
| ATE102482T1 (de) | Verwendung von 1,4-disubstituierten-piperidinyl- verbindungen zur herstellung eines arzneimittels zur behandlung von schlaflosigkeit. | |
| DE69225897D1 (de) | Chinuclidinestern, verfahren und zwischenprodukte zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen | |
| DE59711463D1 (de) | Verwendung von isoxazol- und Crotonsäureamidderivaten zur Modulation der Apoptose | |
| DE69209166D1 (de) | Diclofenac-Cholinsalz, Verfahren zur Herstellung und pharmazeutische Zusammensetzungen, die es enthalten | |
| DE69917668D1 (de) | Substanz gm-95, verfahren zu ihrer herstellung und ihre verwendung | |
| AU683148B2 (en) | Cyclohexane derivatives, process for their preparation, and the use of the compounds for the treatment of diseases | |
| DE69123757D1 (de) | Epoxysuccinamidsäurederivat | |
| HU9601701D0 (en) | Aromatic hydroxamic acid compounds, process for producing them and their use | |
| DE69619088D1 (de) | Quinoxalin-Derivate zur Behandlung von Tinnitus | |
| ATE159517T1 (de) | Verfahren zur herstellung von n-carbonylarylimine als zwischenprodukte in der synthese von therapeutisch aktiven taxol-derivaten | |
| ATE172964T1 (de) | Verfahren zur herstellung von (-)-n-methyl-n-(4- (4-phenyl-4-acetylaminopiperidin-1-yl)-2-(3,4- dichlorophenyl)butyl>-benzamid und ihr pharmazeutisch annehmbares salz | |
| DE69232406D1 (de) | Verfahren zur Herstellung von Fluoro-Chinolin-3-Carbonsäurederivate | |
| ATE281453T1 (de) | 4-amino-2-ureido-pyrimidin-5-carbonsäureamide, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung | |
| DE69616801D1 (de) | Eintopfverfahren zur herstellung von 2-oxazolidinonderivate | |
| ATE120461T1 (de) | Imidazolylpropylguanidinderivat, verfahren zu seiner herstellung und diese verbindung enthaltende arzneimittel. |